Making Good Drugs Great. To build a Biobetter company by taking select biological drugs or their biosimilars and developing long-acting versions of those products. Such novel versions of innovator drugs, whose performance has been enhanced by modifications...Learn More
The drug delivery platform(s) is natural and biocompatible unlike other delivery systems that are synthetic and merely tolerated by the body. Such a platform(s) benefits patients with its non-toxic potential and its ability to increase the half-life of a drug, requiring less frequent administration.Learn More
DNX's pipeline co-development strategy is based on a combination of Internal Product Pipeline Development and Biopharmaceutical Corporate Partnering. The goal is to increase value along the development
chain by way of monetization of select target molecules.
Treatment of rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.
A monoclonal antibody fragment derived from the same parent mouse antibody as bevacizumab. An anti-angiogenic that has been approved for the treatment of age-related wet macular degeneration.
Development of the first, half-life extended version of this proven and safe commercially-approved product to target two new indications: osteoarthritis (OA) and type-2 diabetes. A 330-350 fold increase in half-life over the un-modified molecule has been demonstrated in preclinical data.
Treatment of metabolic diseases and diabetes. Preclinical data suggests that the half-life extended molecule has significantly enhanced pharmacological properties over the un-modified molecule in terms circulating half-life, potency levels and solubility.
A FAb fragment of a recombinant human IgG1 monoclonal antibody used as a TNF inhibiting anti-inflammatory drug for the treatment of RA, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis.